UMPC Hillman Cancer Center

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Head and neck cancer2 trials
• Myeloproliferative neoplasms2 trials
• Acute lymphoblastic leukaemia1 trial
• Acute myeloid leukaemia1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Myelodysplastic syndromes1 trial
• Ovarian cancer1 trial

Phase

• Phase 23 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Completed2 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Dragonfly Therapeutics1 trial
• Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)1 trial
• Kalinski, Pawel, MD, PhD1 trial
• Matthew Spector1 trial
• Sawa Ito, MD1 trial

Running trials

• Recruiting

  Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

  NCT07631650· Phase 2· Matthew Spector· Source

  Contact: Jennifer Ruth, RN, BSN

• Not yet recruiting

  Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

  NCT07634094· Phase 2· Kalinski, Pawel, MD, PhD· Source

  Contact: Kelsey Mitch

• Recruiting

  Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

  NCT07565220· Phase 1· Sawa Ito, MD· Source

  Contact: Amy Rogers, RN, BSN

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Head and neck cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  Study of DF9001 in Patients With Advanced Solid Tumors

  NCT05597839· Phase 1/2· Dragonfly Therapeutics· Source

• Completed

  An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

  NCT05223920· Phase 2· Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)· Source